ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, announced the completion of an oversubscribed $72 million Series B extension financing, bringing the total Series B amount raised to $149 million. The financing expands ROME's investor syndicate to include new investors Johnson & Johnson Innovation-JJDC, Bristol Myers Squibb, Eurofarma Ventures, Luma Group, Mirae Asset Capital, and family offices Raycap and Sigmas Group. Existing investors ARCH Ventures, GV, Section 32, Sanofi Ventures, Andreessen Horowitz, Mass General Brigham Ventures, Casdin Capital, and Alexandria Venture Investments also participated in the round.